Age-standardised incidence rates (ASIR) among females, by age group, in the Lahore district, Pakistan, 2010–2012
| Site (females) | Count 0–14 years | ASIR 0–14 years | Count 15–19 years | ASIR 15–19 years | Count ≥ 20 years | ASIR ≥ 20 years |
| Lip | 0 | 0.0 | 0 | 0.0 | 9 | 0.2 |
| Tongue | 0 | 0.0 | 0 | 0.0 | 129 | 2.8 |
| Mouth | 0 | 0.0 | 3 | 0.2 | 127 | 2.6 |
| Salivary glands | 1 | 0.0 | 0 | 0.0 | 40 | 0.7 |
| Tonsil | 0 | 0.0 | 0 | 0.0 | 8 | 0.2 |
| Nasopharynx | 1 | 0.0 | 2 | 0.1 | 16 | 0.3 |
| Hypopharynx | 0 | 0.0 | 1 | 0.1 | 31 | 0.6 |
| Pharynx | 1 | 0.0 | 0 | 0.0 | 4 | 0.1 |
| Oesophagus | 0 | 0.0 | 1 | 0.1 | 94 | 2.0 |
| Stomach | 0 | 0.0 | 0 | 0.0 | 105 | 2.1 |
| Small intestine | 0 | 0.0 | 0 | 0.0 | 17 | 0.4 |
| Colon | 1 | 0.0 | 5 | 0.3 | 153 | 3.1 |
| Rectum | 1 | 0.0 | 4 | 0.2 | 132 | 2.5 |
| Anus | 0 | 0.0 | 0 | 0.0 | 23 | 0.4 |
| Liver | 3 | 0.1 | 1 | 0.1 | 173 | 4.0 |
| Gall bladder and so on | 0 | 0.0 | 1 | 0.1 | 138 | 3.2 |
| Pancreas | 0 | 0.0 | 1 | 0.1 | 39 | 0.9 |
| Other ill-defined digestive | 1 | 0.0 | 1 | 0.1 | 12 | 0.2 |
| Nose, sinuses | 1 | 0.0 | 2 | 0.1 | 24 | 0.5 |
| Larynx | 0 | 0.0 | 0 | 0.0 | 28 | 0.6 |
| Trachea, bronchus and lung | 2 | 0.0 | 3 | 0.2 | 87 | 2.0 |
| Other thoracic organs | 0 | 0.0 | 1 | 0.1 | 15 | 0.3 |
| Bone | 29 | 0.5 | 22 | 1.4 | 40 | 0.5 |
| Melanoma of the skin | 0 | 0.0 | 0 | 0.0 | 13 | 0.2 |
| Other skin | 1 | 0.0 | 2 | 0.1 | 193 | 4.4 |
| Connective and soft tissue | 19 | 0.3 | 9 | 0.6 | 80 | 1.4 |
| Breast | 3 | 0.0 | 2 | 0.1 | 4077 | 79.2 |
| Vulva | 1 | 0.0 | 0 | 0.0 | 18 | 0.4 |
| Vagina | 0 | 0.0 | 0 | 0.0 | 16 | 0.3 |
| Cervix uteri | 0 | 0.0 | 0 | 0.0 | 247 | 4.8 |
| Corpus uteri | 0 | 0.0 | 0 | 0.0 | 267 | 6.1 |
| Uterus, unspecified | 0 | 0.0 | 0 | 0.0 | 89 | 1.9 |
| Ovary | 12 | 0.2 | 13 | 0.8 | 417 | 7.9 |
| Other female genital organs | 0 | 0.0 | 0 | 0.0 | 18 | 0.4 |
| Placenta | 0 | 0.0 | 0 | 0.0 | 7 | 0.1 |
| Kidney | 15 | 0.3 | 0 | 0.0 | 87 | 1.7 |
| Renal pelvis | 0 | 0.0 | 0 | 0.0 | 1 | 0.0 |
| Ureter | 0 | 0.0 | 0 | 0.0 | 1 | 0.0 |
| Bladder | 1 | 0.0 | 1 | 0.1 | 107 | 2.4 |
| Eye | 23 | 0.5 | 0 | 0.0 | 17 | 0.4 |
| Brain, nervous system | 32 | 0.5 | 14 | 0.9 | 181 | 3.3 |
| Thyroid | 2 | 0.0 | 3 | 0.2 | 210 | 3.5 |
| Adrenal | 2 | 0.0 | 0 | 0.0 | 2 | 0.0 |
| Hodgkin lymphoma | 16 | 0.3 | 7 | 0.4 | 57 | 0.9 |
| Non-Hodgkinlymphoma | 18 | 0.3 | 8 | 0.5 | 251 | 5.3 |
| Multiple myeloma | 0 | 0.0 | 0 | 0.0 | 36 | 0.8 |
| Lymphoid leukaemia | 89 | 1.6 | 5 | 0.3 | 18 | 0.3 |
| Myeloid leukaemia | 13 | 0.2 | 4 | 0.2 | 45 | 0.7 |
| Other leukaemias | 1 | 0.0 | 0 | 0.0 | 1 | 0.0 |
| Leukaemia, unspecified | 21 | 0.4 | 5 | 0.3 | 14 | 0.2 |
| Other and unspecified | 17 | 0.3 | 3 | 0.2 | 516 | 10.8 |
| Benign CNS | 12 | 0.2 | 12 | 0.7 | 164 | 2.8 |
| All sites (n (%)) | 339 (3.7%) | 6.1 | 136 (1.5%) | 8.4 | 8594 (94.7%) | 170.7 |
Incidence rates based on fewer than 10 cases are shown in italics following IARC Cancer Incidence in Five Continents (CI5) practice to indicate unstable incidence rates.
CNS, central nervous system.